
    
      A total of 2070 participants will be enrolled into the trial; 1970 HIV-uninfected and 100
      people living with HIV. There will be 4 trial groups, group 1 (n=50; intensive safety &
      immunogenicity cohort, HIV negative), group 2a (n=250; safety, intense immunogenicity &
      efficacy), group 2b (n=1650; safety, immunogenicity & vaccine efficacy) and group 3 (n=100,
      intensive safety & immunogenicity cohort, HIV positive).

      Participants will be followed up for 12 months after enrollment.
    
  